Characteristics of patients
| Median age, y (range) | 47 (18-70) |
| Sex | |
| Male | 25 |
| Female | 18 |
| Type of disease | |
| Hodgkin disease | 15 |
| Non-Hodgkin lymphoma | 28 |
| Diffuse large B-cell lymphoma | 15 |
| Anaplastic B-cell lymphoma | 2 |
| Grade III B follicular lymphoma | 3 |
| Mantle cell lymphoma | 5 |
| T-cell–rich B-cell lymphoma | 3 |
| Median lines of previous therapy (not comprising salvage therapy before transplantation) | 2 (2-5) |
| Previous therapies (detailed) | |
| Hodgkin lymphoma patients | 15 |
| ABVD | 6 |
| MOPP | 9 |
| BEACOPP | 8 |
| IEV | 7 |
| IGEV | 8 |
| BEAM + ASCT | 3 |
| Non-Hodgkin lymphoma patients | 28 |
| R-CHOP (14 or 21) | 19 |
| R-MegaCHOP | 4 |
| R-MACOP-B | 5 |
| R-MAD | 3 |
| R-ESHAP | 5 |
| R-DHAP | 11 |
| R-IEV | 15 |
| Cyclophosphamide 7 g/m2 | 2 |
| DEXA-BEAM | 2 |
| Disease stage | |
| II | 7 |
| III | 16 |
| IV | 20 |
| IPI score (NHL only) | |
| Intermediate-high | 7 |
| High | 21 |
| Bulky disease? | |
| Yes | 21 |
| No | 22 |
| Disease status at enrolment | |
| Primary refractory | 21 |
| Relapse | 22 |
| Disease status before transplantation | |
| Second or further complete remission, n (%) | 16 (37) |
| Partial response, n (%) | 20 (46) |
| No response/progression, n (%) | 7 (17) |
| Median age, y (range) | 47 (18-70) |
| Sex | |
| Male | 25 |
| Female | 18 |
| Type of disease | |
| Hodgkin disease | 15 |
| Non-Hodgkin lymphoma | 28 |
| Diffuse large B-cell lymphoma | 15 |
| Anaplastic B-cell lymphoma | 2 |
| Grade III B follicular lymphoma | 3 |
| Mantle cell lymphoma | 5 |
| T-cell–rich B-cell lymphoma | 3 |
| Median lines of previous therapy (not comprising salvage therapy before transplantation) | 2 (2-5) |
| Previous therapies (detailed) | |
| Hodgkin lymphoma patients | 15 |
| ABVD | 6 |
| MOPP | 9 |
| BEACOPP | 8 |
| IEV | 7 |
| IGEV | 8 |
| BEAM + ASCT | 3 |
| Non-Hodgkin lymphoma patients | 28 |
| R-CHOP (14 or 21) | 19 |
| R-MegaCHOP | 4 |
| R-MACOP-B | 5 |
| R-MAD | 3 |
| R-ESHAP | 5 |
| R-DHAP | 11 |
| R-IEV | 15 |
| Cyclophosphamide 7 g/m2 | 2 |
| DEXA-BEAM | 2 |
| Disease stage | |
| II | 7 |
| III | 16 |
| IV | 20 |
| IPI score (NHL only) | |
| Intermediate-high | 7 |
| High | 21 |
| Bulky disease? | |
| Yes | 21 |
| No | 22 |
| Disease status at enrolment | |
| Primary refractory | 21 |
| Relapse | 22 |
| Disease status before transplantation | |
| Second or further complete remission, n (%) | 16 (37) |
| Partial response, n (%) | 20 (46) |
| No response/progression, n (%) | 7 (17) |
ABVD indicates adriamycin, bleomycin, vinblastine, and dacarbazine; ASCT, autologous stem cell transplantation; BEACOPP, cyclophosphamide, doxorubicin, etoposide, procarbazine, prenisone, bleomycin, and vincristine; BEAM, bendamustine,etoposide, cytarabine, and melphalan; DEXA-BEAM, dexamethasone, carmustine, etoposide, cytarabine, and melphalan; IEV, ifosfamide, epirubicin, and etoposide; IGEV, Ifosfamide, gemcitabine, and vinorelbine; IPI, International Prognostic Index; MOPP, mechlorethamine, oncovin, procarbazine, and prednisone; NHL, non-Hodgkin lymphoma; R-CHOP, rituximab, vincristine, doxorubicin, hydrochloride, cyclophosphomide, prednisone; R-DHAP, rituximab, dexamethasone, high-dose cytarabine, cisplatin; R-ESHAP, rituximab, etoposide, methylprednisolone, cytarabine, cisplatin; R-IEV, rituximab, ifosfamide, epirubicin, and etoposide; R-MACOP-B, rituximab, vincristine, doxorubicin, hydrochloride, methotrexate, bleonycin, cyclophosphamide, and and prednisolone; R-MAD, rituximab-mitoxantrone-cytarabine-dexamethasone.